Cell and Gene Therapy Clinical Trials

The Promise and Complexity of Living Therapies

909

Get the eBook

Cell and Gene Therapy Clinical Trials eBookThe promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a new era of growth in these advanced therapies.
For the first time, there are more than 1,000 active regenerative medicine and advanced therapy
developers worldwide, and of these companies, 415 are in the clinical stage of development. As the CGT industry accelerates, so will the demand for best practices, and better tools and solutions. For advanced therapies, the product and patient journey is entirely different from traditional trials. As such, biotech and pharma companies will need to overcome challenges and complexities from regulatory pathways and patient recruitment to logistics and manufacturing. CGT therapies also require specialty testing and lab services, including molecular capabilities and immunohistochemistry testing. Adopting strategic partnerships with deep CGT expertise with a broad spectrum of solutions and services is vital to the success of a development program.

 

Sponsor:

ICON logo

This site uses Akismet to reduce spam. Learn how your comment data is processed.